Research Updates on Microneedle-Based Transdermal Drug Delivery Systems
LU Yang1, CHENG Zhu-qiang2, JIN Yi2*, DING Zhi1,3*
Author information+
1. School of Life Sciences, Nanjing University, Nanjing 210023, China; 2. Pain Management, Nanjing General Hospital of Nanjing Command, Nanjing 210002, China; 3. Institute of Biopharmaceutical Technology, Changzhou Institute of Industrial Technology, Nanjing University, Changzhou 213164, China
Microneedle-based transdermal drug delivery system refers to the use of microneedles piercing the stratum corneum of the skin to form tiny pores, through which drug absorption via the skin is enhanced with minimal pain sensation. As a novel drug delivery method, the microneedle technology can significantly improve the transdermal absorption efficiency of the drugs, especially hydrophilic drugs, as compared with using transdermal drug formulations alone. Thus the scope of applicable drugs for transdermal delivery are remarkably enlarged, the efficacy and bioavailability improved as well. Microneedle technology has developed rapidly in the field of transdermal drug delivery. In this paper, the recent representative literature on microneedle-aided transdermal drug administration home and abroad to present the latest progress in this field that was summarized.
LU Yang, CHENG Zhu-qiang, JIN Yi, DING Zhi.
Research Updates on Microneedle-Based Transdermal Drug Delivery Systems[J]. Chinese Pharmaceutical Journal, 2018, 53(12): 945-950 https://doi.org/10.11669/cpj.2018.12.001
[1] BIAN J M, ZENG M, XU J F. Research progress of microneedles in transdermal drug delivery[J]. Chin Pharm J(中国药学杂志), 2006, 41(16):1209-1211. [2] HENRY S, MCALLISTER D V, ALLEN M G, et al. Microfabricated microneedles:a novel approach to transdermal drug delivery[J]. J Pharm Sci, 1998, 87(8):922-925. [3] MAADEN K V D, JISKOOT W, BOUWSTRA J. Microneedle technologies for (trans)dermal drug and vaccine delivery[J]. J Controlled Release, 2012, 161(2):645-655. [4] BAL S M, DING Z, RIET E V, et al. Advances in transcutaneous vaccine delivery:do all ways lead to Rome?[J]. J Controlled Release, 2010, 148(3):266-282. [5] HARDING C R. The stratum corneum:structure and function in health and disease[J]. Dermatol Ther, 2004, 17(suppl 1):6-15. [6] BOUWSTRA J A, PONEC M. The skin barrier in healthy and diseased state[J]. Biochim Biophys Acta, 2006, 1758(12):2080-2095. [7] HUZIL J T, SIVALOGANATHAN S, KOHANDEL M, et al. Drug delivery through the skin:molecular simulations of barrier lipids to design more effective noninvasive dermal and transdermal delivery systems for small molecules, biologics, and cosmetics[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2011, 3(5):449-462. [8] KANITAKIS J. Anatomy, histology and immunohistochemistry of normal human skin[J]. Eur J Dermatol, 2002, 12(4):390-399. [9] DONNELLY R F, RAJ SINGH T R, WOOLFSON A D. Microneedle-based drug delivery systems:microfabrication, drug delivery, and safety[J]. Drug Deliv, 2010, 17(4):187-207. [10] CHEN J, CHEN Z P, QU M M, et al. Application of microneedle technology in transdermal drug delivery[J]. Int J Pharm Res(国际药学研究杂志), 2011, 38(2):142-147. [11] WAN Z, ZHOU J, HAN M N, et al. Research progress of application of microneedle transdermal drug delivery system[J]. J Pharm Pract(药学实践杂志), 2012, 30(2):86-88. [12] NAGUIB Y W, AMIT K, CUI Z. The effect of microneedles on the skin permeability and antitumor activity of topical 5-fluorouracil[J]. Acta Pharm Sin B(药学学报英文), 2014, 4(1):94-99. [13] LI C G, LEE C Y, LEE K, et al. An optimized hollow microneedle for minimally invasive blood extraction[J]. Biomed Microdev, 2013, 15(1):17-25. [14] NANDAGOPAL M S G, ANTONY R, RANGABHASHIYAM S, et al. Overview of microneedle system:a third generation transdermal drug delivery approach[J]. Microsys Technol, 2014, 20(7):1249-1272. [15] CHEN M C, LING M H, KUSUMA S J. Poly-γ-glutamic acid microneedles with a supporting structure design as a potential tool for transdermal delivery of insulin[J]. Acta Biomater, 2015, 24(15):106-116. [16] HIROBE S, AZUKIZAWA H, HANAFUSA T, et al. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch[J]. Biomaterials, 2015, 57:50-58. [17] JIN T. Phase inversion polymer microneedles:China, CN102202720A[P]. 2011-09-28. [18] DONNELLY R F, MORROW D I, MCCARRON P A, et al. Microneedle-mediated intradermal delivery of 5-aminolevulinic acid:potential for enhanced topical photodynamic therapy[J]. J Controlled Release, 2008, 129(3):154-162. [19] QUINN H L, BONHAM L, HUGHES C M, et al. Design of a dissolving microneedle platform for transdermal delivery of a fixed-dose combination of cardiovascular drugs[J]. J Pharm Sci, 2015, 104(10):3490-3500. [20] BAEK S H, SHIN J H, KIM Y C. Drug-coated microneedles for rapid and painless local anesthesia[J]. Biomed Microdev, 2017, 19(1):2-12. [21] ZHAO X, COULMAN S A, HANNA S J, et al. Formulation of hydrophobic peptides for skin delivery via coated microneedles[J]. J Controlled Release, 2017, 265:2-23. [22] SEONG K Y, SEO M S, HWANG D Y, et al. A self-adherent, bullet-shaped microneedle patch for controlled transdermal delivery of insulin[J]. J Controlled Release, 2017,265:48-56. [23] YANG S, WU F, LIU J, et al. Phase-transition microneedle patches for efficient and accurate transdermal delivery of insulin[J]. Adv Funct Mater, 2015, 25(29):4633-4641. [24] YU J, ZHANG Y, YE Y, et al. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery[J]. Proc Natl Acad Sci USA, 2015, 112(27):8260-8265. [25] XU T, WEI M Y, DENG L H, et al. Research progress of transcutaneous immunity[J]. Chin Pharm J(中国药学杂志), 2010, 45(24):1895-1899. [26] EDENS C, COLLINS M L, GOODSON J L, et al. A microneedle patch containing measles vaccine is immunogenic in non-human primates[J]. Vaccine, 2015, 33(37):4712-4718. [27] BEALS C R, RAILKAR R A, SCHAEFFER A K, et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine:an exploratory, randomised, partly blinded trial[J]. Lancet Infect Dis, 2016, 16(8):915-922. [28] CHU L Y, YE L, DONG K, et al. Enhanced stability of inactivated influenza vaccine encapsulated in dissolving microneedle patches[J]. Pharm Res, 2016, 33(4):868-878. [29] KIM Y C, LEE S H, CHOI W H, et al. Microneedle delivery of trivalent influenza vaccine to the skin induces long-term cross-protection[J]. J Drug Target, 2016, 24(10):943-951. [30] KIM E, ERDOS G, HUANG S, et al. Preventative vaccines for zika virus outbreak:preliminary evaluation[J]. Ebio Med, 2016, 13:315-320. [31] WELDON W C, ZARNITSYN V G, EESSER E S, et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine[J]. PLoS One, 2012, 7(7):e41501. [32] YANG H, YE L, GUO X D, et al. Ebola vaccination using a dna vaccine coated on plga-pll/γpga nanoparticles administered using a microneedle patch[J]. Adv Healthc Mater, 2017, 6(1):1600750. [33] ARYA J M, DEWITT K, SCOTT-GARRARD M, et al. Rabies vaccination in dogs using a dissolving microneedle patch[J]. J Controlled Release, 2016, 239:19-26. [34] ROSEMARIE L, FETCHICK D A, MORRIS T L, et al. Use of V-Go® insulin delivery device in patients with sub-optimally controlled diabetes mellitus:a retrospective analysis from a large specialized diabetes system[J]. Diab Ther, 2015, 6(4):531-545. [35] LAJARA R, DAVIDSON J A, NIKKEL C C, et al. Clinical and cost effectiveness of insulin delivery with V-Go® disposable insulin delivery device versus multiple daily injections in patients with type 2 diabetes inadequately controlled on basal insulin[J]. Endoc Pract, 2016, 22(6):726-735.